Core tip: Gastrointestinal bleeding is a common complication of hepatocellular carcinoma (HCC). However, HCC leading to Hepatogastric fistula presenting as massive upper gastrointestinal bleeding is uncommon. Here we report a case of HCC with direct invasion of the stomach leading to massive gastrointestinal bleeding. Patient was managed with selective arterial angiogram and coil embolization to control bleeding. HCC with local metastasis to adjacent structures such gastrointestinal tract carries poor prognosis. With increasing incidence of HCC and recent improvements in the treatment of advanced HCC, this condition may become more common and awareness among clinicians should help consider this condition in the differential diagnosis and prompt management.
INTRODUCTION
Hepatocellular carcinoma (HCC) is an aggressive primary malignancy of the liver with 5-year survival rates as low as 5%[1]. It is the third leading causes of cancer deaths across the world and ninth leading cause of cancer deaths in United States[2]. While the incidence of other common cancers is decreasing in the United States, HCC is on the rise with an average annual percentage change of incidence rate of 3.5%[2]. The majority of cases of HCC are caused by chronic liver disease from hepatitis B and C (78%)[2]. Extra-hepatic metastasis is found at the time of diagnosis in up to 15% of patients with HCC[3]. Lung is the most common site of metastasis followed by intra-abdominal lymph nodes, and bone and adrenal glands[3]. Median survival of patients with extra-hepatic manifestations is less than 6 mo[4]. Metastasis to the gastrointestinal (GI) tract is rare with rates of 0.4%-2% of cases[5] and in up to 12% of cases in autopsy series[6]. Here we report a case of HCC with direct invasion of the stomach leading to massive GI bleeding.
CASE REPORT
A 36-year-old Asian male with hepatitis B and hepatitis C associated HCC presented with chronic melena and massive acute upper GI bleeding with large volume hematemesis. He had undergone trans-arterial chemo-embolization (TACE) four months ago for a large, diffuse, unresectable, biopsy proven HCC in the left lobe of the liver. Due to side effects from the procedure, patient declined to undergo further TACE. He had been on Sorafenib for the preceding two and one-half months prior to this presentation. Apparently, the patient had a liver mass that was resected in his home country eight years ago, described verbally to him as “a benign” tumor. Vital signs on presentation included BP 131/75 mmHg, pulse 123, RR 32, temperature 96.0 F, and oxygen saturation was 88% on 4 L via nasal cannula. On physical exam, he was tachycardic, chest was clear to auscultation; mucus membranes were pale, abdominal exam showed tender hepatomegaly (10 cm below right coastal margin in the mid-clavicular line) and mid-epigastric tenderness. Alpha fetoprotein level was 8.3 ng/mL. Laboratory data revealed hemoglobin of 2.5 g/dL (hematocrit, 10%; mean corpuscular volume 94), leukocytosis (with white blood cell count 16.7), and platelet count of 539. Coagulation profile showed a mildly prolonged INR of 1.6 and activated partial thromboplastin time of 21. Hemoglobin from prior hospitalization 4 mo ago was 13.3 g/dL. The patient was transfused with packed red cells (7 units) and intravenous fluids were administered. Tumor marker studies including α-fetoprotein (7.6 ng/mL), CEA (3.3 ng/mL), and CA 19.9 (< 0.1 U/mL), all of which were normal. Hepatitis B quantitative polymerase chain reaction was 41048 U/mL, hepatitis Be antigen was negative and hepatitis Be antibody was positive. Hepatitis C quantitative PCR was 65 IU/mL.
Abdominal computed tomography with intravenous and oral contrast noted a large left hepatic lobe mass which was increased in size (19 cm × 13 cm) compared to prior mass (16 cm × 10 cm) noted two months earlier. An EGD was performed and revealed a 1.4 cm fistula in the posterior wall of the distal gastric body with stigmata of recent bleeding via the fistula (Figure 1). A large amount of air was seen centrally within the mass, which appeared to communicate with the gastric lumen through a 7 mm defect along the lesser curvature near the gastric fundus (Figure 2). Subsequently, a visceral (celiac, superior mesenteric artery, and left gastric artery) arteriogram demonstrated no evidence of active bleeding. However, selective left gastric artery angiogram showed hypervascular blush within the tumor and it was selectively embolized to achieve decreased flow, utilizing a total of three, 6 mm × 10 cm long Azur detachable coils. His hemoglobin stabilized and he was discharged with plans to start second line palliative chemotherapy. He subsequently presented a month later with recurrent GI bleeding for which he had to undergo further selective embolization of celiac artery branches, which showed signs of neovascularization. The patient opted for hospice care 10 mo after diagnosis of HCC and 6 mo after treatment of acute GI bleed from hepato-gastric fistula.
Figure 1 Esophagogastroduodenoscopy image showing the fistulous opening of the hepatocellular carcinoma on the lesser curvature of the stomach.
Figure 2 Computerized tomography images of the abdomen.
A: Showing large mass in the left lobe of the liver and oral contrast traced into liver (arrow) through fistulous opening in stomach; B: Showing large mass in the left lobe of the liver and fistulous communication between the liver mass and the stomach; C: Showing large mass in the left lobe of the liver and fistulous communication between the liver mass and the stomach. A: Anterior R: Right; L: Left; P: Posterior.
DISCUSSION
GI bleeding is a common complication in patients with HCC. Common etiologies include peptic ulcer disease, variceal bleeding due to portal hypertension from underlying cirrhosis and/or tumor invasion of portal vein causing thrombosis, and portal hypertensive gastropathy. Yeo et al[5] prospectively looked at 55 HCC patients who presented with GI bleeding over a period of 11 mo and found that majority had a non-variceal source of bleeding (53%) and the remainder variceal bleeding. Among patients with a non-variceal source, three patients (0.05%) bled secondary to direct invasion of tumor to gut. GI bleeding secondary to direct invasion by HCC is rare (0.05%-2%)[5,7-9]. Metastatic spread can be due to hematogenous, lymphatic or by direct invasion of the tumor into adjacent organs. The most common site of direct tumor invasion of the GI tract is stomach followed by duodenum and colon. Predisposing factors for GI tract invasion include large liver lesions (> 5 cm in size), sub-capsular location and exophytic growth pattern. Suspected predisposing features include prior TACE and/or radiation therapy which can lead to ischemia and inflammatory reactions in the tumor and adjoining bowel wall. These changes can potentially lead to adhesion and local tumor invasion with subsequent fistulization[10,11]. We hypothesize a similar process in our case. Park et al[6] found GI tract involvement at the time of diagnosis of HCC in 7/12 patients without any prior treatment. In our patient, we suspect an exophytic tumor growth pattern causing direct GI tract invasion and pressure necrosis on adjacent organs. This process was likely worsened by TACE/radiation related inflammatory reactions contributing to erosion and fistulization, with subsequent bleeding into the GI tract. Sources of gastrointestinal bleeding noted in the literature have included rupture of hepatoma into the GI tract, bleeding from the intrahepatic portion of the tumor, or bleeding from an involved vessel in the wall of the GI tract. In our case, we endoscopically documented oozing from the hypervascular edges of the gastro-hepatic fistula within the stomach.
The prognosis of patients with HCC and GI involvement is poor because of massive bleeding and/or hepatic failure. In one series, the median survival was 4 wk[7] and in a second study none survived beyond 9 mo[8]. Our patient survived 6 mo. Non-surgical techniques to achieve hemostasis include trans-arterial embolization, endoscopic injection of ethanol or adrenalin, and radiotherapy ablation. Korkolis et al[12] reported a case of HCC invading the stomach and upper surface of the pancreas who underwent en bloc resection of left lobe of liver with liver mass (15 cm × 12 cm × 9.5 cm), total gastrectomy, distal pancreatectomy, splenectomy, cholecystectomy, radical excision of adjacent lymph node and survival of 16 mo with no local recurrence. Curative surgery is a potential option especially in good surgical candidates with reasonable functional reserve. Surgical intervention has showed prolonged survival with median survival rates of 9.7 mo as opposed to 3.0 mo in non-surgical therapy as reported in other case series[13,14].
In conclusion, due to improvements in chemotherapy and advanced interventional radiologic chemoembolization techniques with improved short term survival in patients with unresectable HCC[15,16], GI tract fistulization and associated upper GI bleeding are likely to become more frequent in the future. This complication may be managed via palliative surgical resection, or by angiographic embolization, as was performed in our patient.
P- Reviewer: Helling T S- Editor: Qi Y L- Editor: A E- Editor: Liu XM
